Functional Organic Cation Transporters Mediate Osteogenic Response to Metformin in Human Umbilical Cord Mesenchymal Stromal Cells.

Faisal E. Al Jofi,Tao Ma,Dong Guo,Monica P. Schneider,Yan Shu,Hockin H. K. Xu,Abraham Schneider

DOI: https://doi.org/10.1016/j.jcyt.2018.02.369

IF: 6.196

2018-01-01

Cytotherapy

Abstract:BACKGROUND:Compelling evidence indicates that metformin, a low-cost and safe orally administered biguanide prescribed to millions of type 2 diabetics worldwide, induces the osteoblastic differentiation of mesenchymal stromal cells (MSCs) through the 5' adenosine monophosphate (AMP)-activated protein kinase (AMPK) pathway. As a highly hydrophilic cationic compound, metformin uptake is facilitated by cell membrane organic cation transporters (OCTs) of the solute carrier 22A gene family. We hypothesized that to effectively enhance osteogenic differentiation, and ultimately bone regeneration, metformin must gain access into functional OCT-expressing MSCs.METHODS:Data was obtained through immunoblotting, cellular uptake, mineralization and gene expression assays.RESULTS:We demonstrate for the first time that functional OCTs are expressed in human-derived MSCs from umbilical cord Wharton's jelly, an inexhaustible source of nonembryonic MSCs with proven osteogenic potential. A clinically relevant concentration of metformin led to AMPK activation, enhanced mineralized nodule formation and increased expression of the osteogenic transcription factor Runt-related transcription factor 2 (RUNX2). Indeed, targeting OCT function through pharmacological and genetic approaches markedly blunted these responses.CONCLUSIONS:Our findings indicate that functional OCT expression in UC-MSCs is a biological prerequisite that facilitates the intracellular uptake of metformin to induce an osteogenic effect. Future pre-clinical studies are warranted to investigate whether the expression of functional OCTs may serve as a potential biomarker to predict osteogenic responses to metformin.